vimarsana.com

Page 20 - அல்லாத சிறிய செல் நுரையீரல் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting Permanent Abstract Number: 1636 Title: Optimized antagonist anti-PD-1/IL-7 mutein bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity. Morello A., Seité M., Durand J, Thépenier V., Teppaz G., Pengam S., Wilhelm E., Desselle A., Girault I., Mary C., Poirier N. Session Type: E-Poster Session Session Title: Therapeutic Antibodies Title: Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis Gauttier V., Lavy M., Trilleaud C., Biteau K., Girault I., Belarif L., Teppaz G., Mary C., Thepenier V., Blanquart C., Barillé-Nion S., Poirier N.

Detecting Hidden Circulating Tumor Cells in Patients With Common Lung Cancer

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer. Now, researchers have designed a new method to detect circulating tumor cells (CTCs), a telltale sign of metastases, in patients with NSCLC.

Novel method can improve the detection of circulating tumor cells

Novel method can improve the detection of circulating tumor cells Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases often go undetected in the blood compared to breast, prostate, colorectal, and other cancers. Now, scientists have developed a novel method to better detect the circulating tumor cells (CTCs) that are a telltale sign of metastases. The research was published in the journal Proceedings of the National Academy of Sciences ( PNAS). ISB and a collaborative team of researchers looked at hexokinase-2, or HK2, a key enzyme in glucose metabolism. A set of previous reports from our collaborator Dr. Herschman (co-author of the paper) and others revealed that cancer cells often rely on HK2 to elevate glucose metabolism to fuel their uncontrolled growth, making this enzyme a desirable target for test

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.